Lorlatinib

Substance active

Lorlatinib (PF-06463922)

Titulaire

Pfizer

Status

closed

Indication

Metastatic NSCLC (Stage IV, AJCC v7.0) that carries an ALK rearrangement or that carries a ROS1 rearrangement

Public documents

Approbation

Information for the patient

Informed consent

Last update

24/12/2020